Champions Oncology Inc Stock Research

Market Summary

USD4.95-0.07

Market Closed

-1.39%

CSBR Stock Price

CSBR RSI Chart

CSBR Valuation

Market Cap

67.1M

Price/Earnings (Trailing)

-21.53

Price/Sales (Trailing)

1.25

EV/EBITDA

-66.01

Price/Free Cashflow

23.62

CSBR Price/Sales (Trailing)

CSBR Profitability

EBT Margin

0.27%

Return on Equity

1.18%

Return on Assets

0.3%

Free Cashflow Yield

4.23%

CSBR Fundamentals

CSBR Revenue

Revenue (TTM)

53.7M

Revenue Y/Y

-3.18%

Revenue Q/Q

-10.56%

CSBR Earnings

Earnings (TTM)

-3.1M

Earnings Y/Y

-409.91%

Earnings Q/Q

-15.1K%

Price Action

52 Week Range

3.759.88

(Low)(High)

Last 7 days

-6.4%

Last 30 days

0.6%

Last 90 days

6.9%

Trailing 12 Months

-31.9%

CSBR Financial Health

Current Ratio

1.1

CSBR Investor Care

Shares Dilution (1Y)

0.43%

Diluted EPS (TTM)

-0.22

Peers (Alternatives to Champions Oncology)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
A	34.8B	6.9B	-13.07%	-9.66%	26.34	5.03	7.53%	9.79%
ILMN	30.7B	4.4B	-5.38%	-24.63%	-6.98	6.91	-4.49%	-677.95%
MTD	29.8B	4.0B	-11.85%	-0.89%	33.62	7.55	3.66%	11.80%
TECH	13.1B	1.1B	4.13%	-13.68%	48.21	11.65	4.39%	20.74%
MID-CAP
RGEN	9.6B	777.8M	14.32%	1.94%	57.47	12.4	5.95%	15.10%
SMALL-CAP
PACB	3.1B	128.3M	16.42%	100.00%	-9.61	24.03	-1.69%	-82.99%
ADPT	1.0B	184.3M	-2.10%	-14.96%	-5.17	5.47	19.29%	17.33%
QTRX	741.0M	104.4M	56.65%	10.37%	-8.75	7.1	-7.50%	-28.77%
NSTG	287.8M	132.0M	-37.96%	-63.90%	-1.78	2.18	-8.69%	-26.95%
HBIO	235.8M	114.5M	-2.27%	49.07%	-117.1	2.06	-5.10%	69.01%
BNGO	211.6M	29.5M	0.25%	-60.59%	-1.51	7.17	43.94%	-51.20%
CDXS	156.7M	116.2M	-40.05%	-78.73%	-3.28	1.35	-4.78%	-132.67%
CDXC	104.5M	77.3M	6.06%	-22.22%	-9.77	1.35	10.46%	61.07%
CSBR	67.1M	53.7M	0.61%	-31.91%	-21.53	1.25	14.70%	-1523.74%

Financials for Champions Oncology

* denotes actual numbers (not divided by Thousands)
Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-0.8%	53,676	54,096	51,601	49,109	46,796
Operating Expenses	5.3%	56,722	53,854	51,103	48,502	46,526
S&GA Expenses	3.2%	6,768	6,556	6,496	6,379	6,235
R&D Expenses	9.9%	11,284	10,263	9,958	9,374	8,855
EBITDA	-3.4%	2,200	2,277	2,210	1,650	-
EBITDA Margin	-7.8%	0.04*	0.04*	0.05*	0.04*	-
Earnings Before Taxes	-2175.7%	-3,072	148	439	583	288
EBT Margin	-67.8%	0.00*	0.01*	0.01*	0.01*	-
Net Income	-2987.0%	-3,118	108	401	548	219
Net Income Margin	-74.3%	0.00*	0.01*	0.01*	0.01*	-
Free Cahsflow	52.4%	5,875	3,855	4,113	989	-

* denotes actual numbers (not divided by Thousands)
Balance Sheet					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-0.6%	36,151	36,364	34,390	35,378	33,584
Current Assets	-1.2%	20,359	20,608	18,371	19,664	17,825
Cash Equivalents	7.4%	11,600	10,800	8,100	9,007	8,701
Net PPE	0.1%	7,708	7,698	7,134	6,991	-
Goodwill	0%	335	335	335	335	335
Liabilities	7.0%	29,087	27,192	25,407	26,282	24,348
Current Liabilities	11.0%	20,797	18,736	16,620	17,479	15,499
Shareholder's Equity	-23.0%	7,064	9,172	8,983	9,096	9,236
Retained Earnings	-3.5%	-74,800	-72,300	-72,300	-71,982	-71,600
Additional Paid-In Capital	0.4%	81,806	81,475	81,270	81,064	80,860
Accumulated Depreciation	-	5,577	-	-	-	-
Shares Outstanding	0%	13,559	13,559	13,522	13,559	13,500

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-33.0%	5,460	8,153	6,086	6,497	3,721
Share Based Compensation	2.6%	844	823	838	912	885
Cashflow From Investing	-15.4%	-2,618	-2,269	-2,231	-2,384	-2,712
Cashflow From Financing	-40.0%	102	170	205	207	263

Risks for CSBR

What is the probability of a big loss on CSBR?

94.2%

Probability that Champions Oncology stock will be more than 20% underwater in next one year

86.5%

Probability that Champions Oncology stock will be more than 30% underwater in next one year.

43.9%

Probability that Champions Oncology stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CSBR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Champions Oncology was unfortunately bought at previous high price.

Drawdowns

Returns for CSBR

Cumulative Returns on CSBR

26.6%

10-Year Cumulative Returns

5.9%

7-Year Cumulative Returns

1.4%

5-Year Cumulative Returns

-19.9%

3-Year Cumulative Returns

What are the long-term rolling returns for CSBR?

FIve years rolling returns for Champions Oncology.

Annualized Returns

Which funds bought or sold CSBR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-22	AMERIPRISE FINANCIAL INC	unchanged	-	-40,280	324,720	-%
2023-05-18	JPMORGAN CHASE & CO	unchanged	-	-	-	-%
2023-05-16	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	reduced	-10.74	-21,293	82,888	-%
2023-05-15	CITADEL ADVISORS LLC	reduced	-67.16	-121,271	50,186	-%
2023-05-15	Royal Bank of Canada	added	1,025	7,000	7,000	-%
2023-05-15	VANGUARD GROUP INC	unchanged	-	-33,323	273,388	-%
2023-05-15	GEODE CAPITAL MANAGEMENT, LLC	added	-	-24,181	202,819	-%
2023-05-15	MILLENNIUM MANAGEMENT LLC	added	1.78	-25,000	242,000	-%
2023-05-15	NEA Management Company, LLC	unchanged	-	-839,723	6,889,150	0.48%
2023-05-15	BATTERY MANAGEMENT CORP.	unchanged	-	-1,186,620	9,735,120	1.40%

Latest Funds Activity

Are funds buying CSBR calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own CSBR

No. of Funds

Champions Oncology News

Schedule 13G FIlings of Champions Oncology

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2022	west elk partners, lp	8.09%	1,093,387	SC 13G/A
Jul 23, 2021	west elk partners, lp	5.06%	676,944	SC 13G

CSBR Fair Value

Show Fair-Value

Recent SEC filings of Champions Oncology

View All Filings

Date Filed	Form Type	Document
Apr 05, 2023	8-K	Current Report
Mar 21, 2023	4	Insider Trading
Mar 16, 2023	10-Q	Quarterly Report
Mar 15, 2023	8-K	Current Report

Latest Insider Trading transactions for CSBR

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-17	Morris Ronnie	bought	49,968	4.0356	12,382	ceo
2022-10-19	ACKERMAN JOEL	acquired	53,501	3.21	16,667	-
2022-10-12	Breitfeld Philip P.	sold (taxes)	-26,750	7.51	-3,562	-
2022-10-12	Breitfeld Philip P.	acquired	26,748	3.21	8,333	-
2022-10-12	SIDRANSKY DAVID	sold (taxes)	-26,750	7.51	-3,562	-
2022-10-12	SIDRANSKY DAVID	acquired	26,748	3.21	8,333	-
2022-10-12	TOBIN SCOTT R	acquired	32,100	3.21	10,000	-
2021-10-15	SIDRANSKY DAVID	acquired	26,500	1.59	16,667	-
2021-10-15	SIDRANSKY DAVID	sold (taxes)	26,500	10.08	2,629	-
2021-10-12	TOBIN SCOTT R	acquired	15,900	1.59	10,000	-

About Champions Oncology

Ronnie Morris

www.championsoncology.com

190

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

CSBR Income Statement

2023-01-31

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2023	Jan. 31, 2022
Income Statement [Abstract]
Oncology services revenue	$ 12,773	$ 13,193	$ 40,799	$ 36,232
Costs and operating expenses:
Cost of oncology services	7,699	6,406	22,194	17,411
Research and development	3,202	2,181	8,693	6,783
Sales and marketing	1,761	1,549	5,153	4,764
General and administrative	2,569	2,227	7,494	6,356
Total costs and operating expenses	15,231	12,363	43,534	35,314
Income (loss) from operations	(2,458)	830	(2,735)	918
Other income (loss)	36	(32)	9	11
Income (loss) before provision for income taxes	(2,422)	798	(2,726)	929
Provision for income taxes	17	11	48	37
Net income (loss)	$ (2,439)	$ 787	$ (2,774)	$ 892
Net income (loss) per common share outstanding
Net (income) loss per common share outstanding, basic (in dollars per share)	$ (0.18)	$ 0.06	$ (0.20)	$ 0.07
Net (income) loss per common share outstanding, diluted (in dollars per share)	$ (0.18)	$ 0.05	$ (0.20)	$ 0.06
Weighted average common shares outstanding
Weighted average common shares outstanding, basic (in shares)	13,558,642	13,500,444	13,532,990	13,170,880
Weighted average common shares outstanding, diluted (in shares)	13,558,642	14,387,009	13,532,990	14,178,082
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Cost, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]

CSBR Balance Sheet

2023-01-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2023	Apr. 30, 2022
Current assets:
Cash	$ 11,645	$ 9,007
Accounts receivable, net	8,053	9,513
Prepaid expenses and other current assets	661	1,144
Total current assets	20,359	19,664
Operating lease right-of-use assets, net	7,590	8,230
Property and equipment, net	7,852	7,134
Other long-term assets	15	15
Goodwill	335	335
Total assets	36,151	35,378
Current liabilities:
Accounts payable	4,298	2,868
Accrued liabilities	2,031	2,414
Current portion of operating lease liabilities	1,166	1,054
Other current liability	144	72
Deferred revenue	13,158	11,071
Total current liabilities	20,797	17,479
Non-current operating lease liabilities	7,702	8,412
Other non-current liabilities	588	391
Total liabilities	29,087	26,282
Stockholders’ equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 13,558,650 shares issued and outstanding as of January 31, 2023 and April 30, 2022, respectively	14	14
Additional paid-in capital	81,806	81,064
Accumulated deficit	(74,756)	(71,982)
Total stockholders’ equity	7,064	9,096
Total liabilities and stockholders’ equity	$ 36,151	$ 35,378